Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

Item

http://www.wikidata.org/entity/Q36453663

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@ast

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@en

type

Item

label

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@ast

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@en

prefLabel

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@ast

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@en

P1476

Second-Line Irinotecan, Leucov ...... after Failed Docetaxel and S-1

@en

P2093

Baek-Yeol Ryoo

http://www.w3.org/2001/XMLSchema#string

Boram Han

http://www.w3.org/2001/XMLSchema#string

Dae Young Zang

http://www.w3.org/2001/XMLSchema#string

Ho Suk Kang

http://www.w3.org/2001/XMLSchema#string

Hong Il Ha

http://www.w3.org/2001/XMLSchema#string

Hunho Song

http://www.w3.org/2001/XMLSchema#string

Hyeong Su Kim

http://www.w3.org/2001/XMLSchema#string

Hyun Lim

http://www.w3.org/2001/XMLSchema#string

Ji Woong Cho

http://www.w3.org/2001/XMLSchema#string

Joo Young Jung

http://www.w3.org/2001/XMLSchema#string

P2860

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

P304

6857625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/6857625

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288917583

http://www.w3.org/2001/XMLSchema#string

P698

26839542

http://www.w3.org/2001/XMLSchema#string

P932

4709667

http://www.w3.org/2001/XMLSchema#string